Article - 11/05/2008 New strategy against cervical cancer The German Cancer Research Centre and the Spanish company Chimera Pharma SL have signed an exclusive licensing and cooperation agreement. The two partners will develop a therapeutic vaccine against cervical cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/new-strategy-against-cervical-cancer
Article - 06/05/2008 Vetter clients can concentrate fully on their core business The Ravensburg-based company Vetter Pharma-Fertigung GmbH & Co. KG is one of the leaders in biopharmaceutical contract manufacturing. We spoke with Max Horn, who has been with the company since 1981 and was appointed Managing Director in 2002.https://www.gesundheitsindustrie-bw.de/en/article/news/vetter-clients-can-concentrate-fully-on-their-core-business
Article - 26/04/2008 Huge success for BioValley Organisers and more than 300 participants were very enthusiastic about the European BioFine life sciences congress recently held in Freiburg. Four different life sciences conferences were organised . Freiburg will also host BioFine 2009.https://www.gesundheitsindustrie-bw.de/en/article/press-release/huge-success-for-biovalley
Dossier - 24/04/2008 Contract manufacture: the order books remain full The market for therapeutic proteins is continuing to grow in double figures. Current estimates of the total market value are in the range of 60 to 70 billion US dollars and the market is estimated to grow by 13 per cent p.a. up until 2010. Biopharmaceutical contract manufacturers have established themselves on the market and market observers estimate that the number of biopharmaceutical medicines will grow from 100 2005 to approx. 150 until 2010.https://www.gesundheitsindustrie-bw.de/en/article/dossier/contract-manufacture-the-order-books-remain-full
Press release - 08/04/2008 Boehringer Ingelheim continues to grow Boehringer Ingelheim enjoyed continued success in 2007 and its growth is outpacing the pharmaceuticals market for the eighth year in a row. The companys turnover rose by 8.8 in local currency to almost EUR 11 billion.https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-continues-to-grow
Article - 17/03/2008 FDA approves Vetter Pharma client drug Vetter Pharma Fertigung GmbH Co has been granted approval by the American Food and Drug Administration FDA for the production of a new client drug. Vetter will now be filling injection systems with the new drug at its Ravensburg facility. Vetter has invested over 100 million euros.https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approves-vetter-pharma-client-drug
Press release - 09/02/2008 Pharma and life sciences industry as growth sector The CEOs of pharmaceutical and life science companies are becoming increasingly aware that their companies are facing growing challenges and risks at the global level. At the same time they are also aware of more and more opportunities. https://www.gesundheitsindustrie-bw.de/en/article/press-release/pharma-and-life-sciences-industry-as-growth-sector
Article - 08/02/2008 Nycomed and Wyeth announce launch of an own generic version of PROTONIX® – lawsuit to defend patent continues Nycomed and its licence holder Wyeth Pharmaceuticals a division of Wyeth NYSEWYE today announced the U.S. launch of an own generic version of PROTONIX Pantoprazole tablets in response to the at-risk launch of generic Pantoprazole tablets by Teva Pharmaceuticals USA Inc.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-and-wyeth-announce-launch-of-an-own-generic-version-of-protonix-lawsuit-to-defend-patent-con
Press release - 21/01/2008 Micro-biolytics GmbH - Top spectroscopy technology for the pharmaceutical industry Micro-biolytics GmbH now based in the Esslingen-based Life Science Centre develops and produces microsystems solutions for bioanalytical issues. With the support of networks micro-biolytics is hoping to considerably expand its activities.https://www.gesundheitsindustrie-bw.de/en/article/press-release/micro-biolytics-gmbh-top-spectroscopy-technology-for-the-pharmaceutical-industry
Article - 06/01/2008 Heinrich Planck: experienced interdisciplinarity Only a few researchers combine different disciplines as effectively and with as much flair as Professor Dr.-Ing. Heinrich Planck director of the ITV Denkendorf. He combines mechanical textile and medical engineering both on the scientific and economic level at the same time as being a dedicated networker.https://www.gesundheitsindustrie-bw.de/en/article/news/heinrich-planck-experienced-interdisciplinarity